ATXI
Avenue Therapeutics, Inc.
Set alert
0.38 USD 0.00 0.00%
0.40 Day range 0.40
0.15 52-week range 0.9233
- YTD
- -44.13%
- 1 year
- -46.87%
- Open
- 0.40
- Prev close
- 0.38
- Mkt cap
- 1.25M
- Vol
- 5.00K
- Avg vol
- 5.85K
- EPS
- -0.85
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.40
- High
- 0.40
- Forward P/E
- -0.55
- Beta
- -0.18
- Short ratio
- 0.73
- Inst. own
- 10.33%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.02
- 200-d avg
- 4.18
- 1y target
- 8.00
Key statistics
- Market cap
- 3.53M
- Enterprise value
- -3.09M
- Trailing P/E
- 0.07
- Forward P/E
- -0.55
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.37
- EPS (TTM)
- 24.78
- Beta
- -0.18
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -13.07M
- Total cash
- 4.92M
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 2.05M
- Short % of float
- 3.56%
- 50-day average
- 2.02
- 200-day average
- 4.18
Analyst view
Consensus: none
Price target (mean) 8.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
ATXI Revenue — quarterly 0
ATXI Net income — quarterly -3.08M
ATXI EPS — quarterly -1.92
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -1.92 | — | — |
| Aug 9, 2024 | Jun 1, 2024 | 0.00 | -6.43 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -15.40 | — | — |
| Mar 18, 2024 | Dec 1, 2023 | 0.00 | 42.11 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | 4.51 | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | -39.10 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2023 | Maxim Group | init | — | Buy |
| Apr 3, 2023 | Aegis Capital | init | — | Buy |
About Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- avenuetx.com
News
- Avenue Therapeutics (NASDAQ:ATXI) and Collegium Pharmaceutical (NASDAQ:COLL) Head-To-Head Survey
- Comparing Avenue Therapeutics (NASDAQ:ATXI) & Graybug Vision (NASDAQ:GRAY)
- Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
- Reviewing Avenue Therapeutics (NASDAQ:ATXI) and Endonovo Therapeutics (OTCMKTS:ENDVD)
- Contrasting ObsEva (NASDAQ:OBSV) & Avenue Therapeutics (NASDAQ:ATXI)
- NexImmune (NASDAQ:NEXI) versus Avenue Therapeutics (NASDAQ:ATXI) Head-To-Head Comparison
- Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on ATXI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DAVIDOW ROBERT L | Beneficial Owner of more than 10% of a Class of Security | Sale | Dec 10, 2023 | 0 |
| FORTRESS BIOTECH, INC. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Apr 15, 2024 | 3,547,390 |
| HERSKOWITZ NEIL | Director | Sale | Dec 1, 2024 | 97 |
| JIN DAVID | Chief Operating Officer | Stock Award(Grant) | Sep 22, 2024 | 65,000 |
| KRANZLER JAY D | Director | Sale | Nov 4, 2024 | 559 |
| MACLEAN ALEXANDRA M.D. | Chief Executive Officer | Stock Award(Grant) | Sep 22, 2024 | 170,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 5.60% | 115,000 | 197.80K | Sep 29, 2024 |
| Sabby Management, LLC | 3.07% | 63,060 | 108.46K | Sep 29, 2024 |
| Moss Adams Wealth Advisors LLC | 0.54% | 11,000 | 18.92K | Sep 29, 2024 |
| UBS Group AG | 0.30% | 6,143 | 10.56K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.08% | 1,740 | 2.99K | Sep 29, 2024 |
| Wells Fargo & Company | 0.03% | 561 | 964 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.32% | 6,593 | 11.34K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.08% | 1,584 | 2.72K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.03% | 618 | 1.06K | Sep 29, 2024 |